Oragenics, Inc. develops antibiotics for infectious diseases in the United States.
Share Price & News
How has Oragenics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: OGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: OGEN underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: OGEN underperformed the US Market which returned 33.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Oragenics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Oragenics Fundamentals Summary
|OGEN fundamental statistics|
Is OGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OGEN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.21|
|Net Profit Margin||0.00%|
How did OGEN perform over the long term?See historical performance and comparison
Is Oragenics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OGEN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OGEN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: OGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OGEN is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (3.2x).
How is Oragenics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if OGEN's revenue is forecast to grow faster than the US market.
High Growth Revenue: OGEN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OGEN's Return on Equity is forecast to be high in 3 years time
How has Oragenics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OGEN is currently unprofitable.
Growing Profit Margin: OGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OGEN is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare OGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: OGEN has a negative Return on Equity (-54.81%), as it is currently unprofitable.
How is Oragenics's financial position?
Financial Position Analysis
Short Term Liabilities: OGEN's short term assets ($34.7M) exceed its short term liabilities ($2.1M).
Long Term Liabilities: OGEN's short term assets ($34.7M) exceed its long term liabilities ($398.2K).
Debt to Equity History and Analysis
Debt Level: OGEN is debt free.
Reducing Debt: OGEN has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OGEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OGEN has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 22.5% each year.
What is Oragenics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Sullivan (65 yo)
Mr. Michael O. Sullivan, also known as Mike, CPA has been the Chief Financial Officer, Secretary and Treasurer of Oragenics, Inc. since February 06, 2012 and has been its Interim Principal Executive Office...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD532.21K) is about average for companies of similar size in the US market ($USD545.00K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Experienced Management: OGEN's management team is considered experienced (3.5 years average tenure).
Experienced Board: OGEN's board of directors are seasoned and experienced ( 12.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 90.5%.
Oragenics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Oragenics, Inc.
- Ticker: OGEN
- Exchange: NYSEAM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$74.051m
- Shares outstanding: 116.19m
- Website: https://www.oragenics.com
Number of Employees
- Oragenics, Inc.
- 4902 Eisenhower Boulevard
- Suite 125
- United States
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The compa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 22:31|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.